Influenza Virus Vaccine

BIOLOGICAL10 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Novartis Vaccines, Novartis, Seqirus, Sanofi Pasteur, a Sanofi Company

Conditions

HIV InfectionsHealthy ParticipantsInflammationInfluenzaInfluenza Disease; FluInfluenza, Human

Phase 1

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

CompletedNCT06382311

GlaxoSmithKlineInfluenza, Human

Start: 2024-04-18End: 2026-01-13Updated: 2026-02-05

Phase 2

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

CompletedNCT00264576

Novartis VaccinesInfluenza Disease; Flu

Start: 2005-10-31End: 2006-05-31Updated: 2017-03-24

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

CompletedNCT02649192

St. Jude Children's Research HospitalHealthy Participants

Start: 2016-01-21End: 2018-06-29Updated: 2019-10-29

Phase 3

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

CompletedNCT00464672

NovartisInfluenza

Start: 2007-04-30End: 2007-12-31Updated: 2015-10-01

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

CompletedNCT00700193

SeqirusInfluenza

Start: 2005-03-31Updated: 2016-07-19

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

CompletedNCT00885105

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2005-10-31End: 2007-09-30Updated: 2016-04-14

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

CompletedNCT01551810

Institute of Medical Biology, Chinese Academy of Medical SciencesInfluenza

Start: 2012-03-31End: 2012-08-31Updated: 2023-10-11

Phase 4

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

CompletedNCT00835926

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2003-07-31End: 2003-09-30Updated: 2016-04-14

Unknown Phase

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

WithdrawnNCT00001080

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-01

Vaccine Efficacy in Diabetic and Elderly Patients

CompletedNCT02675608

Tulane UniversityInflammation

Start: 2015-08-31Updated: 2017-01-13

Related Papers

Safety and effectiveness assessment of 2011–2012 seasonal influenza vaccine produced in China: a randomized trial

Postgraduate Medicine2017-08-213 citations

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

2012-06-015 citations